Allogeneic stem cell transplantation in patients with myelofibrosis harboring the MPL mutation.
Daniele ManninaNico GagelmannAnita BadbaranMarkus DitschkowskiRashit BogdanovMarie RobinBruno CassinatMichael HeuserRabia ShahswarFelicitas TholDietrich BeelenNicolaus KrögerPublished in: European journal of haematology (2019)
These retrospective data suggest that MPL-mutated myelofibrosis patients have a favorable outcome after allogeneic transplantation with very low rate of disease relapse (5.5%) in comparison with the available historical controls regarding myelofibrosis in all.